Codagenix Inc. is a clinical-stage biotechnology company specializing in the development of prophylactic vaccines and oncolytic virus therapies. The company operates in the healthcare and biotechnology markets, focusing on creating live attenuated vaccines and viruses to prevent viral infections and treat solid tumors. Codagenix uses a proprietary synthetic biology platform to recode the genomes of viruses, ensuring that their vaccine candidates are a perfect antigenic match to the target virus. This approach induces a robust immune response to all viral antigens, making their vaccines both safe and effective. The company serves a diverse range of clients, including healthcare providers, research institutions, and pharmaceutical companies. Codagenix generates revenue through the development and licensing of its patented vaccine technologies and oncolytic virus therapies. The company's business model is centered around innovation in vaccine design, leveraging its exclusive patents and proprietary technology to maintain a competitive edge in the market.

Keywords: synthetic biology, live attenuated vaccines, oncolytic virus therapies, prophylactic vaccines, genome recoding, viral infections, solid tumors, healthcare, biotechnology, patent licensing.